Clinical pharmacology of NVP
In the context of attempts to simplify treatment regimens and enhance adherence, there is great interest in once-daily (QD) dosing regimens for the treatment of HIV-infected patients. Nevirapine (NVP) has a long plasma half-life and high steady state plasma concentrations meaning that it may be a suitable candidate for once-daily use.
Parts of this CME:
start of the CME
Pharmacokinetics
2NN: efficacy
Other clinical sudies on NVP QD efficacy
Transition from BID to QD: clinical data
The future
Conclusions